Straight out of the Trump book of obfuscation19 Jan 2023 15:30
From what I can see from certain posters on here there is clearly a pattern - used many times by trolls before - to create FUD by the mischievous use of positive, published data. In our case there is the obvious attempt to throw dust over the fact that we have MORE - not less - data than would be expected from a standard Phase 1a trial yet the trolls come up with things such as 'yeah, but that doesn't mean it works just because it's found in the biopsy' etc .etc. In other words, they are creating issues which have little or nothing at all to do with a data rich, PHASE 1a trial. The FUD is added to by the 'follow the squiggly lines' cult (ie chartists) who add fuel to the fire with their 'it must drop back to fill a gap' pronouncements which become self-fulfilling when they all do what the 'squiggly lines' tell them to do and sell. No wonder the MMs love them as it makes their job so much easier and more profitable.
As all researched LTHs here know the primary purpose of a Phase 1a trial is to evaluate safety and everything else is a bonus. However, since AVA6000 is based around a well-researched 'warhead' (doxorubicin) the novel aspects lie in the targetting of the tumour and delivery mechanism - leaving healthy tissue unaffected. The fact that we have extra data from a closely supervised Phase 1a reflects the confidence of both our own company scientists and the safety committee supported by the results of the pre-clinical trials which have now found support in the Phase 1a trial. We are therefore ahead - not behind the curve - as far as data gathering is concerned.
Establishing an MTD will of course be interesting but if the profile of the pre-clinical trials is replicated then the tolerance levels will be far higher than 'straight dox' as ably demonstrated by others here. Also, at this stage I would not expect Avacta to say more than they need to in respect of cleaving or potential degree of tumour shrinkage. That, for a number of reasons, remains commercially sensitive in my view and in any case is for later trials to determine. If you release too much early data you can attract the attention of unwelcome predators who if nothing else can distract attention and waste valuable corporate time better spent elsewhere. So if there is no further news until Science Day I do not expect any sudden revelations on that day.
Sign In
Follow the stocks
